Wednesday, July 8, 2026

Patent intelligence · US

US 7511053

Spiroazacyclic compounds as monoamine receptor modulators

granted A61PA61P1/14A61P25/00A61P25/06
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 3
Applicant portfolio 77
Patent details — US 7511053
Jurisdiction
US
Status
granted
Grant date
Mar 31, 2009
Expiration
Mar 26, 2029
Claims
24
CPC classes
A61P, A61P1/14, A61P25/00, A61P25/06
View on Google Patents ↗

Quick answer

US 7511053 (Spiroazacyclic compounds as monoamine receptor modulators) is held by ACADIA Pharmaceuticals Inc.. Status: granted. Granted Mar 31, 2009. Expires Mar 26, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
24
CPC classes
A61P, A61P1/14, A61P25/00, A61P25/06, A61P25/14, A61P25/16

More from ACADIA Pharmaceuticals Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 11844764

    Agitation process for preparing a carbetocin drug product

    ACADIA Pharmaceuticals Inc. · Expires Dec 14, 2043

    granted
  2. US 11827600

    Crystalline forms of trofinetide

    ACADIA Pharmaceuticals Inc. · Expires Nov 23, 2043

    granted
  3. US 11464768

    Pimavanserin alone or in combination for use in the treatment of Alzheimer's disease psychosis

    ACADIA Pharmaceuticals Inc. · Expires Oct 6, 2042

    granted
  4. US 11452721

    Formulations of pimavanserin

    ACADIA Pharmaceuticals Inc. · Expires Sep 22, 2042

    granted
  5. US 11191757

    Combination of pimavanserin and cytochrome P450 modulators

    ACADIA Pharmaceuticals Inc. · Expires Dec 2, 2041

    granted
  6. US 11161826

    Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

    ACADIA Pharmaceuticals Inc. · Expires Oct 28, 2041

    granted
  7. US 11135211

    Pimavanserin for treating impulse control disorder

    ACADIA Pharmaceuticals Inc. · Expires Sep 30, 2041

    granted
  8. US 11091473

    Compounds for pain treatment, compositions comprising same, and methods of using same

    ACADIA Pharmaceuticals Inc. · Expires Aug 12, 2041

    granted

Frequently asked questions

What is US patent 7511053?

US 7511053 (Spiroazacyclic compounds as monoamine receptor modulators) is held by ACADIA Pharmaceuticals Inc.. Status: granted. Granted Mar 31, 2009. Expires Mar 26, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7511053?

ACADIA Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 77 pharmaceutical patents for this assignee.

When does US 7511053 expire?

Our index shows an expiration date of Mar 26, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.